DISCOVERY OF FDA-APPROVED DRUGS AS INHIBITORS OF FATTY ACID BINDING PROTEIN 4 USING MOLECULAR DOCKING SCREENING

摘要

Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.